Close Menu
October 21, 2019
Sponsored by
Agilent

Broad Genomic Testing for Oncology Clinical Trials and Clinical Practice

Genome Webinar

Head of Medical Genomics,
Glasgow Precision Oncology Laboratory

Genomics is a key element in the potential of precision medicine to transform oncology. Hybrid-capture based targeted next-gen sequencing (NGS) represents a particularly promising option for cancer genomic testing, as it enables the profiling of all cancer-relevant events with the advantage of being compatible with formalin-fixed, paraffin-embedded (FFPE) tissue.

The Glasgow Precision Oncology Laboratory (GPOL) has defined the content required to capture the full range of clinically and biologically important genomic events that characterize solid tumors and turned these into a range of SureSelect cancer NGS assays, the first of which, dubbed Cancer Core, will be presented during this webinar.

In this webinar, Dr. Cooke, head of Medical Genomics of the GPOL shares:

  • How the GPOL has built affordable, fit-for-purpose, cancer NGS solutions using the SureSelect target enrichment platform, specifically to address the challenges of real-world oncology.
  • How the GPOL is implementing broad genomic testing as part of its mission to accelerate the translation of novel cancer therapeutics from discovery to clinical applications.

 For Research Use Only. Not for use in diagnostic procedures.

Sponsored by
Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
23
Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
25
Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

Apr
08
Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.